Singapore markets closed

Axsome Therapeutics, Inc. (0HKF.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
79.48+0.74 (+0.93%)
At close: 04:41PM GMT
Full screen
Previous close78.75
Open81.00
Bid0.00 x 0
Ask0.00 x 0
Day's range77.22 - 81.00
52-week range55.64 - 98.17
Volume111
Avg. volume562
Market cap25.695M
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)-3.72
Earnings date06 May 2024 - 10 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    30 Countries with the Lowest Depression Rates

    In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]

  • Insider Monkey

    20 Cloudiest Cities in the U.S., Ranked

    In this article, we will take a look at the top 20 cloudiest cities in the U.S., Ranked. If you would like to skip our discussion on the diverse weather patterns across the country, you can go to the 5 Cloudiest Cities in the U.S., Ranked. Ranking fourth in terms of land area globally, the […]

  • GlobeNewswire

    Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

    77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI) Depression and anxiety were experienced by 45% and 57% of narcolepsy type 1 patients, respectiv